facebook
spears_logo

Top Recommended
Click to explore ranking

tatler_logo

Featured in
The Tatler Address Book

doctify_logo

Outstanding
Click to see reviews

spears_logo
tatler_logo
doctify_logo

Our Audited Macular Oedema Outcomes: 0.03% in 3,215 Procedures

2 min read

Over a nine-year audited period at Blue Fin Vision®, covering 3,215 cataract and refractive lens replacement procedures, we recorded one case of clinically significant CMO.

That incidence of 0.03% sits markedly below typical ranges reported in the literature, where clinical CMO rates around 1–2% are described in routine populations and higher rates in diabetics and other high-risk groups.¹

The single case in our series occurred in the second eye of a patient who had developed CMO after first-eye surgery elsewhere. We used extended steroid–NSAID prophylaxis for two months; oedema arose only after drops were stopped and resolved once treatment resumed. No other clinically significant cases occurred during the audited period.

While direct institutional comparisons always require caution, this experience supports the association between structured OCT screening, sustained combination therapy and very low clinical CMO incidence.²

References

  1. Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of macular edema after cataract surgery. Ophthalmology. 2016;123(2):316-323.
  2. Henderson BA, Kim JY, Ament CS, et al. Clinical pseudophakic CMO risk factors. J Cataract Refract Surg. 2007;33(9):1550-1558.

Related Topics

Return to Knowledge Base

About Blue Fin Vision®

Blue Fin Vision® is a GMC-registered, consultant-led ophthalmology clinic with CQC-regulated facilities across London, Hertfordshire, and Essex. Patient outcomes are independently audited by the National Ophthalmology Database, confirming exceptionally low complication rates.